Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Monday, October 18, 2010

FDA Approved Entecavir in Decompensated HBV Patients

U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease

Viral load reduction at 48 weeks in difficult-to-treat chronic hepatitis B patient population 

 Read More

No comments:

Post a Comment